Danaher Exceeds Q1 Expectations Amid Market Uncertainty, Driven by Bioprocessing and Diagnostics Growth
SHERIDAN, WYOMING – May 1, 2025 – Danaher Corporation (NYSE: DHR), a global science and technology leader, reported first-quarter 2025 financial results that exceeded expectations across revenue, earnings, and cash flow, underscoring the strength of its diversified portfolio and operational excellence amid a dynamic macroeconomic environment.
Total revenue for the quarter reached $5.7 billion, reflecting a modest 1.0% year-over-year decline. However, non-GAAP core revenue remained flat compared to Q1 2024, signaling underlying stability. Net earnings stood at $1.0 billion, or $1.32 per diluted share, while adjusted diluted net earnings per share reached $1.88. Free cash flow for the quarter totaled $1.1 billion, reinforcing Danaher’s strong cash generation capabilities.
Strong Segment Performance and Resilience in Diagnostics